MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Clinical trials for MULTIPLE SCLEROSIS, RELAPSING-REMITTING explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE SCLEROSIS, RELAPSING-REMITTING trials appear
Sign up with your email to follow new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
MS treatment showdown: does early aggressive therapy prevent disability better?
Disease control OngoingThis study looks at whether starting strong medications early for relapsing-remitting multiple sclerosis (MS) works better than the usual step-up approach to prevent long-term disability. About 900 adults aged 18-60 with MS are taking part. Researchers are tracking disability pro…
Matched conditions: MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Phase: NA • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated May 17, 2026 00:28 UTC
-
New pill aims to stop MS Flare-Ups in their tracks
Disease control OngoingThis study tests an oral medication called IMU-838 against a placebo in about 1,100 adults with relapsing multiple sclerosis (MS). The goal is to see if the drug can reduce the number of relapses (flare-ups) and limit new brain damage seen on MRI scans. Participants take the pill…
Matched conditions: MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Phase: PHASE3 • Sponsor: Immunic AG • Aim: Disease control
Last updated May 17, 2026 00:28 UTC
-
Real-World test: does kesimpta® keep MS relapses at bay?
Disease control OngoingThis study looks at how well the drug ofatumumab (Kesimpta®) works for people with relapsing-remitting multiple sclerosis (RRMS) in real-life settings in Italy. About 379 adults who already started the drug as part of their normal care will be followed for 12 months. The main goa…
Matched conditions: MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 00:25 UTC
-
MS patients switch meds – will it work as well?
Disease control OngoingThis study looks at 184 people with relapsing-remitting multiple sclerosis who switched from the drug MabThera to a similar drug called Rixathon. Researchers want to see if the switch changes nerve damage, brain lesions, relapses, or disability. They will use existing medical rec…
Matched conditions: MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Sponsor: Uppsala University • Aim: Disease control
Last updated May 17, 2026 00:24 UTC
-
New hope for kids with MS: drug trial aims to cut relapses
Disease control OngoingThis study tests an experimental drug called BIIB017 in children aged 10 to 17 with relapsing-remitting multiple sclerosis (MS). The goal is to see if the drug can reduce the number of MS attacks (relapses) and is safe for long-term use. Participants will receive either BIIB017 o…
Matched conditions: MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Diet showdown: could keto or paleo ease MS symptoms?
Symptom relief OngoingThis study looks at whether following a special diet (either a time-restricted keto diet with olive oil or a modified Paleo diet) can improve quality of life for people with relapsing-remitting multiple sclerosis compared to standard dietary guidelines. About 162 participants wil…
Matched conditions: MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Phase: NA • Sponsor: Terry L. Wahls • Aim: Symptom relief
Last updated Apr 26, 2026 20:00 UTC
-
Can a breathing trick boost electrical stimulation for MS?
Knowledge-focused OngoingThis study looks at whether a special breathing technique (AIH) combined with mild electrical stimulation (NMES) can improve brain signals and ankle strength in people with relapsing forms of multiple sclerosis. About 40 participants will be tested to see if the combination works…
Matched conditions: MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Phase: NA • Sponsor: Shirley Ryan AbilityLab • Aim: Knowledge-focused
Last updated May 17, 2026 00:29 UTC
-
Hidden immune cells in lymph nodes may resist MS drug, new study investigates
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether the MS drug ocrelizumab effectively removes B cells from lymph nodes, not just from the blood. Researchers will analyze lymph node samples from 5 people with relapsing-remitting MS who are starting ocrelizumab. The goal is to understand why some immune…
Matched conditions: MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated May 15, 2026 11:53 UTC